4.7 Article

Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

Journal

CLINICAL CANCER RESEARCH
Volume 17, Issue 16, Pages 5490-5500

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-0724

Keywords

-

Categories

Funding

  1. NIH/NIGMS [U01GM61393, U01GM61374, K08GM089941]
  2. University of Chicago Breast Cancer SPORE [P50 CA125183]
  3. NCI [R21 CA139278]
  4. University of Chicago Cancer Center [P30 CA14599]
  5. Breast Cancer SPORE Career Development award
  6. Pritzker School of Medicine Experience in Research (PSOMER)
  7. National Heart Lung and Blood Institute [NHLBI 2 T35 HL07764]
  8. U.S. Army Medical Research and Materiel Command [DAMD17-01-1-0729]
  9. National Health and Medical Research Council (NHMRC) of Australia
  10. Cancer Council Victoria
  11. Cancer Council Queensland
  12. Cancer Council New South Wales
  13. Cancer Council South Australia
  14. Cancer Foundation of Western Australia
  15. Cancer Council Tasmania
  16. NHMRC [496675]
  17. Cancer Research UK [C536/A6689]
  18. [R01 CA122443]
  19. [P50 CA136393]
  20. Cancer Research UK [13086] Funding Source: researchfish

Ask authors/readers for more resources

Purpose: Cell-based approaches were used to identify genetic markers predictive of patients' risk for poor response prior to chemotherapy. Experimental Design: We conducted genome-wide association studies (GWAS) to identify single-nucleotide polymorphisms (SNP) associated with cellular sensitivity to carboplatin through their effects on mRNA expression using International HapMap lymphoblastoid cell lines (LCL) and replicated them in additional LCLs. SNPs passing both stages of the cell-based study were tested for association with progression-free survival (PFS) in patients. Phase 1 validation was based on 377 ovarian cancer patients receiving at least four cycles of carboplatin and paclitaxel from the Australian Ovarian Cancer Study (AOCS). Positive associations were then assessed in phase 2 validation analysis of 1,326 patients from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Results: In the initial GWAS, 342 SNPs were associated with carboplatin-induced cytotoxicity, of which 18 unique SNPs were retained after assessing their association with gene expression. One SNP (rs1649942) was replicated in an independent LCL set (Bonferroni adjusted P < 0.05). It was found to be significantly associated with decreased PFS in phase 1 AOCS patients (Pper-allele = 2 x 10(-2)), with a stronger effect in the subset of women with optimally debulked tumors (Pper-allele = 4 x 10(-3)). rs1649942 was also associated with poorer overall survival in women with optimally debulked tumors (Pper-allele = 9 x 10(-3)). However, this SNP was not significant in phase 2 validation analysis with patients from numerous cohorts. Conclusion: This study shows the potential of cell-based, genome-wide approaches to identify germline predictors of treatment outcome and highlights the need for extensive validation in patients to assess their clinical effect. Clin Cancer Res; 17(16); 5490-500. (C)2011 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available